FindTrial
Sign In

Glycosylated fibronectin test in first trimester to predict chances of preeclampsia

First trimester maternal serum glycosylated fibronectin as a predictor of preeclampsia-A Descriptive Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/033066
Enrollment
100
Registered
2021-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O149- Unspecified pre-eclampsia

Interventions

None listed

Sponsors

Dr Vomica Kewalramani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Multigravida with Gestational age-11-14 weeks with singleton pregnancy

Exclusion criteria

Exclusion criteria: K/c/o pre eclampsia K/c/o gestational hypertension K/c/o renal disease K/c/o liver disease

Design outcomes

Primary

MeasureTime frame
To evaluate the potential clinical utility of serum biochemical marker glycosylated fibronectin for prediction of preeclampsia in first trimesterTimepoint: 3 months—

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable—

Countries

India

Contacts

Public ContactDr M B Bellad
belladmb@gmail.com9448124893

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026